---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-006880"
form_type: "8-K"
ticker: "ATAI"
cik: "0002081043"
company_name: "AtaiBeckley Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:53:04.152222+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AtaiBeckley reports positive Phase 2a results for EMP-01 in Social Anxiety Disorder; LSAS -11.85 vs placebo

## Summary
- EMP-01 met primary safety objective; no serious AEs, no suicidal behavior.
- LSAS placebo-adjusted reduction of 11.85 points at Day 43 (Hedges' g=0.45, p=0.036 one-tailed).
- CGI-I responders: 49% EMP-01 vs 15% placebo; NNT 2.95.
- Improvements in both Fear (-13.7) and Avoidance (-15.1) subscales after two doses without psychotherapy.
- 71 patients enrolled, 69 completed Day 43 with high retention.

## SEC filing metadata
- accession: 0001140361-26-006880
- form_type: 8-K
- ticker: ATAI
- cik: 0002081043
- company_name: AtaiBeckley Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2081043/000114036126006880/0001140361-26-006880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2081043/000114036126006880/ef20066456_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-006880
- JSON: https://secwatch.observer/filing/0001140361-26-006880.json
- Plain text: https://secwatch.observer/filing/0001140361-26-006880.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.